SRS06, a new semisynthetic andrographolide derivative with improved anticancer potency and selectivity, inhibits nuclear factor-kB nuclear binding in the A549 non-small cell lung cancer cell line

Background: Andrographolide has been reported with anticancer and anti-inflammatory properties through the inhibition of the activity of signaling molecules such as v-Src, nuclear factor-κB (NF-κB), STAT3, and PI3K. NF-κB has been proven to promote cancer cell survival, and targeting this pathway will halt the growth of cancer cells. Efforts have been made to produce semisynthetic derivatives of andrographolide with improved anticancer potency and selectivity. Subsequently, the effect of a selected derivative, 3,14,19-tripropionylandrographolide (SRS06), was tested for its action against NF-κB. Methods: Screening against 60 US National Cancer Institute (NCI) human cancer cell lines representing leukemia and non-small cell lung (NSCL), colon, CNS, melanoma, ovarian, renal, prostate, and breast cancers was performed to determine the tumor type selectivity and potency of SRS06. Microculture tetrazolium, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and sulforhodamine B assays were used to determine the in vitro anticancer activity, while Western blot studies were performed to ascertain the inhibitory effect of SRS06 on the NF-κB signaling cascade. The TransAM™ p65 assay kit was used to determine NF-κB p65 DNA binding activity in the NSCL cancer cell line A549. Results: From the NCI screening, SRS06 was found to exhibit potent growth-inhibitory effects on multiple cancer cell lines with 10-fold lower 50% growth inhibition (GI50) compared with andrographolide. It was also discerned that the compound preferentially targeted melanoma, CNS, renal, colon, ovarian, prostate, and NSCL cancer cell lines. The DNA fragmentation assay indicated that the main mode of cell death of SRS06-treated A549 cells was via apoptosis. At 5 µmol/l the compound decreased NF-κB protein expression and caused a significant reduction in the nuclear p65 DNA binding activity. Conclusion: SRS06 displayed improved anticancer selectivity and potency when compared with andrographolide. We alluded its anticancer activity to its effect of inhibiting NF-κB nuclear binding

USE OF ARTEMISININ DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

US20120015922A1Published Applicatio

USE OF ANDROGRAPHOLIDE COMPOUNDS FOR TREATING INFLAMMATION AND AIRWAY DISORDERS

EP2411004A1Published Applicatio

Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD

10.1016/j.coph.2019.04.010CURRENT OPINION IN PHARMACOLOGY4673-8

Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases

10.1016/j.coph.2017.12.002CURRENT OPINION IN PHARMACOLOGY40Sep-1

ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION

EP1660682B1Granted Paten

Calcaratarin D, a labdane diterpenoid, attenuates mouse asthma via modulating alveolar macrophage function

10.1111/bph.15993BRITISH JOURNAL OF PHARMACOLOGY180

Specificity and Inhibitory Mechanism of Andrographolide and Its Analogues as Antiasthma Agents on NF-kappa B p50

10.1021/np5007179JOURNAL OF NATURAL PRODUCTS782208-217UNITED KINGDO

Ultrastructural Characteristics of DHA-Induced Pyroptosis

10.1007/s12017-019-08586-yNEUROMOLECULAR MEDICINE222293-30

Scavenging circulating mitochondrial DNA as a potential therapeutic option in multiple organ dysfunction in trauma hemorrhage

10.3389/fimmu.2018.00891.eCollectionFrontiers in Immunology9891-891Switzerlan